Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

MLA

Zhu, Liancheng, et al. “Dacomitinib (PF-00299804), a Second-Generation Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, Demonstrates Remarkable Activity against HER2-Amplified Uterine Serous Endometrial Cancer in Vitro.” Tumor Biology (Springer Science & Business Media B.V.), vol. 36, no. 7, July 2015, pp. 5505–13. EBSCOhost, https://doi.org/10.1007/s13277-015-3218-4.

APA

Zhu, L., Lopez, S., Bellone, S., Black, J., Cocco, E., Zigras, T., Predolini, F., Bonazzoli, E., Bussi, B., Stuhmer, Z., Schwab, C., English, D., Ratner, E., Silasi, D.-A., Azodi, M., Schwartz, P., Rutherford, T., & Santin, A. (2015). Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology (Springer Science & Business Media B.V.), 36(7), 5505–5513. https://doi.org/10.1007/s13277-015-3218-4

Chicago

Zhu, Liancheng, Salvatore Lopez, Stefania Bellone, Jonathan Black, Emiliano Cocco, Tiffany Zigras, Federica Predolini, et al. 2015. “Dacomitinib (PF-00299804), a Second-Generation Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, Demonstrates Remarkable Activity against HER2-Amplified Uterine Serous Endometrial Cancer in Vitro.” Tumor Biology (Springer Science & Business Media B.V.) 36 (7): 5505–13. doi:10.1007/s13277-015-3218-4.